Prospective Grant of Exclusive License: Antibody Therapeutics for the Treatment of Cancer in Humans, 25021 [E8-9873]

Download as PDF Federal Register / Vol. 73, No. 88 / Tuesday, May 6, 2008 / Notices Date: June 17, 2008. Time: 7:45 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: The Westin Tysons Corner, 7801 Leesburg Pike, Falls Church, VA 22043. Contact Person: Ilda M. Mckenna, PhD, Scientific Review Officer, Research Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 8111, Bethesda, MD 20892, 301–496–7481, mckennai@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: April 29, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–9879 Filed 5–5–08; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Antibody Therapeutics for the Treatment of Cancer in Humans National Institutes of Health, Public Health Service, HHS. ACTION: Notice. rwilkins on PROD1PC63 with NOTICES AGENCY: SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the invention embodied in U.S. Patent Application Number 11/895,326, filed August 24, 2007, entitled ‘‘Tumor Markers in Ovarian Cancer’’ [E–138–2000/0–US– 05]; to Morphotek, Incorporated, having a place of business at Exton, PA. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be worldwide, and the field of use may be limited to antibodies developed by Licensee’s proprietary Human MORPHODOMA antibody technology or via humanization for anticlaudin-3 antibody therapeutics for ovarian cancer. DATES: Only written comments and/or applications for a license which are received by the NIH Office of VerDate Aug<31>2005 17:11 May 05, 2008 Jkt 214001 25021 Technology Transfer on or before July 7, 2008 will be considered. DEPARTMENT OF HOMELAND SECURITY Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Jennifer Wong, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435– 4633; Facsimile: (301) 402–0220; E-mail: wongje@mail.nih.gov. Transportation Security Administration ADDRESSES: The technology relates to claudin-3 as an ovarian cancer biomarker. Claudin-3 was identified as a biomarker utilizing SAGE analysis comparing ovarian epithelial tumor cells and normal ovarian epithelial cells. Claudin-3 is a member of a family of transmembrane proteins associated with tight junctions and its function has been associated with invasive ovarian cancer. Inhibition of claudin-3 is a potential therapeutic for the treatment of metastatic ovarian cancer. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. SUPPLEMENTARY INFORMATION: Dated: April 29, 2008. David Sadowski, Deputy Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E8–9873 Filed 5–5–08; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00084 Fmt 4703 Sfmt 4703 [Docket Nos. TSA–2006–24191; Coast Guard–2006–24196] Transportation Worker Identification Credential (TWIC); Enrollment Dates for the Ports of Houma, LA; Morgan City, LA; Calcite, MI; San Francisco, CA; and Kansas City, MO Transportation Security Administration; United States Coast Guard; DHS. ACTION: Notice. AGENCY: SUMMARY: The Department of Homeland Security (DHS) through the Transportation Security Administration (TSA) issues this notice of the dates for the beginning of the initial enrollment for the Transportation Worker Identification Credential (TWIC) for the Ports of Houma, LA; Morgan City, LA; Calcite, MI; San Francisco, CA; and Kansas City, MO. DATES: TWIC enrollment begins in Houma on May 7, 2008; Morgan City on May 9, 2008; Calcite and San Francisco on May 14, 2008; and Kansas City on May 15, 2008. ADDRESSES: You may view published documents and comments concerning the TWIC Final Rule, identified by the docket numbers of this notice, using any one of the following methods. (1) Searching the Federal Docket Management System (FDMS) Web page at https://www.regulations.gov; (2) Accessing the Government Printing Office’s Web page at https:// www.gpoaccess.gov/fr/; or (3) Visiting TSA’s Security Regulations Web page at https:// www.tsa.gov and accessing the link for ‘‘Research Center’’ at the top of the page. FOR FURTHER INFORMATION CONTACT: James Orgill, TSA–19, Transportation Security Administration, 601 South 12th Street, Arlington, VA 22202–4220. Transportation Threat Assessment and Credentialing (TTAC), TWIC Program, (571) 227–4545; e-mail: credentialing@dhs.gov. Background The Department of Homeland Security (DHS), through the United States Coast Guard and the Transportation Security Administration (TSA), issued a joint final rule (72 FR 3492; January 25, 2007) pursuant to the Maritime Transportation Security Act (MTSA), Pub. L. 107–295, 116 Stat. 2064 (November 25, 2002), and the Security and Accountability for Every Port Act of E:\FR\FM\06MYN1.SGM 06MYN1

Agencies

[Federal Register Volume 73, Number 88 (Tuesday, May 6, 2008)]
[Notices]
[Page 25021]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-9873]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Antibody Therapeutics for 
the Treatment of Cancer in Humans

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department 
of Health and Human Services, is contemplating the grant of an 
exclusive patent license to practice the invention embodied in U.S. 
Patent Application Number 11/895,326, filed August 24, 2007, entitled 
``Tumor Markers in Ovarian Cancer'' [E-138-2000/0-US-05]; to Morphotek, 
Incorporated, having a place of business at Exton, PA. The patent 
rights in these inventions have been assigned to the United States of 
America.
    The prospective exclusive license territory may be worldwide, and 
the field of use may be limited to antibodies developed by Licensee's 
proprietary Human MORPHODOMA[supreg] antibody technology or via 
humanization for anti-claudin-3 antibody therapeutics for ovarian 
cancer.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before July 
7, 2008 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: Jennifer Wong, Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; 
Telephone: (301) 435-4633; Facsimile: (301) 402-0220; E-mail: 
wongje@mail.nih.gov.

SUPPLEMENTARY INFORMATION: The technology relates to claudin-3 as an 
ovarian cancer biomarker. Claudin-3 was identified as a biomarker 
utilizing SAGE analysis comparing ovarian epithelial tumor cells and 
normal ovarian epithelial cells. Claudin-3 is a member of a family of 
transmembrane proteins associated with tight junctions and its function 
has been associated with invasive ovarian cancer. Inhibition of 
claudin-3 is a potential therapeutic for the treatment of metastatic 
ovarian cancer.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, the NIH receives 
written evidence and argument that establishes that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: April 29, 2008.
David Sadowski,
Deputy Director, Division of Technology Development and Transfer, 
Office of Technology Transfer, National Institutes of Health.
[FR Doc. E8-9873 Filed 5-5-08; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.